Efalizumab -Genentech/XOMA
Alternative Names: Anti-CD11a monoclonal antibody - Genentech/Xoma; HU 1124; Hu1124; Raptiva; Xanelim™Latest Information Update: 05 Nov 2023
At a glance
- Originator Genentech
- Developer Genentech; Merck Serono; XOMA
- Class Monoclonal antibodies
- Mechanism of Action CD11a antigen antagonists; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Psoriasis
- Discontinued Psoriatic arthritis; Type 1 diabetes mellitus
Most Recent Events
- 11 Jun 2009 Withdrawn for Psoriasis in Canada (SC)
- 08 Jun 2009 Withdrawn for Psoriasis in European Union (SC)
- 08 Apr 2009 Withdrawn for Psoriasis in USA (SC)